R&D Systems™ Recombinant Mouse OX40/TNFRSF4 Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Manufacturer: R&D Systems™ 1256OX050
DescriptionMeasured by its ability to inhibit OX40 Ligand induced IL-2 secretion by mouse T cells. The ED50 for this effect is 0.1-0.3 μg/mL in the presence of 30 ng/mL of Recombinant Mouse OX40 Ligand/TNFSF4 (Catalog # 1236-OX ).
This product(s) resides on a Fisher Scientific GSA or VA contract. If you are viewing this page as a nonregistered user, the price(s) displayed is List Price. To view your GSA or VA contract pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. You can also view your contract price by searching for this item(s) on GSA Advantage. To place an order, contact Fisher Scientific Customer Service.
|OX40/TNFRSF4 Fc Chimera|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|<0.10 EU / 1 µg of the protein by the LAL method.|
|Reconstitute at 100 µg/mL in sterile PBS.|
|Lyophilized from a 0.2 µm filtered solution in PBS.|
|M.W. (Observed): 65-75 kDa, reducing conditions; M.W. (theoretical): 48 kDa (monomer)|
|>95%, by SDS-PAGE under reducing conditions and visualized by silver stain|
|Mouse myeloma cell line, NS0-derived mouse OX40/TNFRSF4 protein Murine OX40 (Val20-Pro211) (N-terminus) Accession # P47741 DIEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok